Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.

Journal of medical case reports - 12 Oct 2023

Bozan Ersin, Darçın Tahir, Yaman Samet, Yiğenoğlu Tuğçe Nur, Kızıl Çakar Merih, Dal Mehmet Sinan, Altuntaş Fevzi

Abstract excerpt

BACKGROUND: Erdheim Chester disease (ECD) is a rare disease with multisystemic involvement in the group of non-langerhans cell histiocytosis. Although nearly 100 years have passed since its definition, the number of cases reported all over the world is below 1000. In addition to the rarity of the disease, low awareness seems to play a role in this. CASE PRESENTATION: 47-year-old white caucasian women patient who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erdheim-Chester Disease
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 37821987
DOI: 10.1186/s13256-023-04153-z
PMCID: PMC10568759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.PMID 37821987Read ↗

Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.Semantic proximity Read ↗

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.Semantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.Semantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.Semantic proximity Read ↗

From a Long-Standing Yellowish Plaque to a Diagnosis of a Rare Disorder: A Case of Erdheim-Chester Disease Treated With Vemurafenib.Semantic proximity Read ↗

Erdheim-Chester disease: a rapidly evolving disease model.Semantic proximity Read ↗

Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis.Semantic proximity Read ↗

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.Semantic proximity Read ↗

The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.Semantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.